CYTOGENETIC CHARACTERIZATION OF CHRONIC MYELOID LEUKEMIA AND ITS PROGNOSTIC IMPACT UPON TREATMENT WITH TYROSINE KINASE INHIBITORS

被引：0

作者：

Canamero, Giro Eloi ^{[1
]}

Garcia, Olga ^{[1
]}

Boque, Concepcion ^{[2
]}

Sitges, Marta ^{[3
]}

Vallansot, Rolando Omar ^{[4
]}

Cisneros, Adela ^{[1
]}

Cortes, Montserrat ^{[5
]}

Gener, Georgina ^{[6
]}

Vela, Dolors ^{[7
]}

Font, Llorenc ^{[8
]}

Pineda, Alberto ^{[9
]}

Xandri, Marisol ^{[1
]}

Santafe, Encarnacion ^{[1
]}

Espasa, Andrea ^{[1
]}

Comes, Martina ^{[1
]}

Xicoy, Blanca ^{[1
]}

Zamora, Lurdes ^{[1
]}

Granada, Isabel ^{[1
]}

Navarro, Jose Tomas ^{[1
]}

Grau, Javier ^{[1
]}

机构：

[1] Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, Inst Catala Oncol, Inst Recerca Leucemia Josep Carreras, Barcelona, Spain

[2] ICO Hosp Duran & Reynals, Lhospitalet De Llobregat, Spain

[3] ICO Hosp Univ Josep Trueta, Girona, Spain

[4] Hosp Univ Joan XXIII, Tarragona, Spain

[5] Hosp Granollers, Granollers, Spain

[6] Hosp Mataro, Mataro, Spain

[7] Hosp Mollet del Valles, Mollet, Spain

[8] Hosp Verge de la Cinta, Tortosa, Spain

[9] Hosp Esperit St, Santa Coloma, Spain

来源：

HAEMATOLOGICA | 2020年 / 105卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PO-057

引用

页码：169 / 170

页数：2

共 50 条

[1] Role of cytogenetic studies in the treatment of chronic myeloid leukemia by tyrosine kinase inhibitors.
Domracheva, E. V.
Aseeva, E. A.
GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2007, 52 (02): : 25 - 28
[2] Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Tolomeo, Manlio
Dieli, Francesco
Gebbia, Nicola
Simoni, Daniele
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (08) : 853 - 863
[3] Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors
Gugliotta, Gabriele
Castagnetti, Fausto
Fogli, Miriam
Cavo, Michele
Baccarani, Michele
Rosti, Gianantonio
EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (05) : 563 - 574
[4] New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Kimura, Shinya
Ashihara, Eishi
Maekawa, Taira
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2006, 7 (05) : 371 - 379
[5] Tyrosine kinase inhibitors in chronic myeloid leukemia
Sawyers, CL
Druker, B
CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1999, 5 (02): : 63 - 69
[6] PROGNOSTIC VALUE OF CYTOGENETIC ABNORMALITIES ASSOCIATED TO PHILADELPHIA CHROMOSOME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS
Jimenez-Rolando, M.
Garcia-Gutierrez, J. V.
Herrera, P.
Lopez, J.
Calbacho, M.
Blanchard, M. J.
Chinea, A.
Delgado, I.
Alonso, J. M.
Velasco, D.
Odriozola, J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 533 - 533
[7] When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Pierre Laneuville
Current Treatment Options in Oncology, 2018, 19
[8] When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Laneuville, Pierre
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (03)
[9] ASSESSMENT OF EFFICACY OF TYROSINE KINASE INHIBITORS IN TREATMENT OF CHRONIC MYELOID LEUKEMIA
Yadrikhinskaya, V. N.
Mulina, I. I.
Sannikova, A. N.
Palshina, A. M.
Sleptsova, S. S.
Aleksandrova, T. N.
YAKUT MEDICAL JOURNAL, 2016, (04): : 30 - 33
[10] Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
Baccarani, Michele
Castagnetti, Fausto
Gugliotta, Gabriele
Palandri, Francesca
Rosti, Gianantonio
EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (03) : 397 - 406

← 1 2 3 4 5 →